Modelling and optimizing combination therapeutic strategies for KRAS- and EGFR-mutant lung cancer

Area of Science:

• Oncology
• Computational Biology
• Precision Medicine

Background:

• Non-small cell lung cancer (NSCLC) presents high incidence and genetic diversity, necessitating advanced therapeutic approaches.
• Targeted therapies (e.g., kinase inhibitors for EGFR, KRAS) and immunotherapies (immune checkpoint inhibitors, ICIs) have advanced NSCLC treatment.
• Drug resistance and suboptimal response rates in NSCLC underscore the need for novel therapeutic strategies.

Purpose of the Study:

• To develop a Boolean network model for simulating non-small cell lung cancer (NSCLC) patient responses to various treatments.
• To evaluate the efficacy of combining kinase inhibitors and immunological interventions in silico.
• To identify optimal therapeutic strategies for NSCLC based on mutational background.

Main Methods:

• Development of a Boolean network model to simulate biological processes in NSCLC.
• Incorporation of key kinase mutation inhibitors and immunological interventions into the model.
• Validation of simulation results using a quantitative model, mouse studies, and clinical trial data (KRYSTAL-7).

Main Results:

• Boolean network and quantitative model simulations indicated that a combination of KRAS inhibitor and ICI is optimal for KRAS-mutant NSCLC.
• Simulation findings align with existing preclinical (mouse models) and clinical (KRYSTAL-7 phase-2) data.
• The study demonstrates the potential of computational modeling in refining precision oncology treatments.

Conclusions:

• Computational modeling, specifically Boolean networks, offers a valuable tool for optimizing NSCLC treatment strategies.
• Combined KRAS inhibition and ICI therapy shows promise for KRAS-mutant NSCLC patients.
• Further clinical validation, such as the KRYSTAL-7 phase-3 trial, is expected to confirm these findings.